Figure 4

Kaplan-Meier survival analysis by KAI1/CD82 status (n = 83). (A) The green line represents the KAI1/CD82-positive patient group with a trend of better survival than the blue line representing the KAI1/CD82-negative patient group (log-rank = 40.279, P = 0.000). Mean overall survival (OS) time was 76.0 months for the KAI1/CD82-positive group and 45.5 months for the KAI1/CD82-negative group. (B) The green line represents the KAI1/CD82-positive patient group with a trend of better survival than the blue line representing the KAI1/CD82-negative group patients (log-rank = 39.271, P = 0.000). Mean DFS patients was 68.0 months for the KAI1/CD82-positive group and 40.1 months for the KAI1/CD82-negative group.